Protocol Library

Peptide Protocol Library

Every compound in our catalog has a protocol record. Published records show what the sources actually report; everything else is openly marked as still being researched.

Protocol records: 58
Source verified: 58
Citations on file: 163
Last reviewed: 2026-09-16

Educational reference only. Peptides Made Clear does not provide medical advice, dosing recommendations or administration guidance. Values shown are what published sources or reviewed records report, never a suggestion for personal use.

Browse the protocol library

Showing 58 of 58 protocol records.

Cinematic 3D visualization of the stomach, pancreas, liver and abdominal tissue with illuminated metabolic pathways.

5-amino-1-methylquinolinium

Single peptideSource verified

Evidence: Animal research
Route: Subcutaneous (animal research), Oral (community-reported)
Schedule: Once to three times daily in animal studies
Vials: 10 mg

View protocol7 citations

Cinematic 3D visualization of the human brain with glowing synaptic activity and neural pathways.

Single peptideSource verified

Evidence: Laboratory research
Route: Sold as an intranasal or injectable research chemical.
Schedule: Not established.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D macro cross-section of skin layers, collagen fibers and a hair follicle.

Single peptideSource verified

Evidence: Animal research
Route: Research vials and cosmetic-formulation products are sold. No approved or studied human route exists.
Schedule: Not established. No human study exists.
Vials: 50 mg

View protocol2 citations

Cinematic 3D visualization of the stomach, pancreas, liver and abdominal tissue with illuminated metabolic pathways.

Acadesine (5-aminoimidazole-4-carboxamide ribonucleotide)

Single peptideSource verified

Evidence: Animal research
Route: Human trials used intravenous infusion in hospital settings. Research vials are sold online; no approved or studied human vial route exists.
Schedule: Not established for any non-hospital use. No human study of vial-format use exists.
Vials: 50 mg

View protocol6 citations

Cinematic 3D visualization of the stomach, pancreas, liver and abdominal tissue with illuminated metabolic pathways.

Single peptideSource verified

Evidence: Animal research
Route: Studied orally in the obesity programme. Injectable forms sold online are unapproved and were not the subject of the pivotal trials.
Schedule: Trials used daily oral administration over 12 to 24 weeks.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of skeletal muscle fiber bundles and tendons with illuminated recovery pathways.

ARA-290 (cibinetide), an 11-amino-acid innate repair receptor agonist derived from erythropoietin helix B

Single peptideSource verified

Evidence: Early human research
Route: Subcutaneous injection in the published phase 2 human trials; intravenous in some earlier work
Schedule: Phase 2 trials used daily subcutaneous administration over defined study periods of roughly four to twenty-eight days depending on the protocol.
Vials: 4 mg, 16 mg

View protocol6 citations

Cinematic 3D visualization of skeletal muscle fiber bundles and tendons with illuminated recovery pathways.

BlendSource verified

Evidence: Laboratory research
Route: Vendor listings describe subcutaneous injection of a reconstituted blend. No approved route exists for the combination.
Schedule: Not established for the combination. Any schedule shown by a seller is a marketing convention, not a studied regimen.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of skeletal muscle fiber bundles and tendons with illuminated recovery pathways.

Pentadecapeptide BPC 157 (GEPPPGKPADDAGLV)

Single peptideSource verified

Evidence: Early human research
Route: Oral tablet and intravenous infusion in the published human studies; intraperitoneal and intragastric in the rodent literature
Schedule: Not established for any human indication. The registered human studies were dose-escalation safety designs, not schedules intended for repeated use.
Vials: 5 mg, 10 mg

View protocol6 citations

Cinematic 3D visualization of skeletal muscle fiber bundles and tendons with illuminated recovery pathways.

BPC-157 + GHK-Cu + TB-500 + KPV Blend (Klow)

BlendSource verified

Evidence: Laboratory research
Route: Vendor listings describe subcutaneous injection of a reconstituted blend. No approved route exists for the combination.
Schedule: Not established for the combination. Any schedule shown by a seller is a marketing convention, not a studied regimen.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of the stomach, pancreas, liver and abdominal tissue with illuminated metabolic pathways.

Single peptideSource verified

Evidence: Controlled human trials
Route: Subcutaneous injection, in every published human trial
Schedule: Once weekly in the published trial programme
Vials: 5 mg, 10 mg

View protocol6 citations

Cinematic 3D visualization of the human heart and vascular network with illuminated circulation.

Single peptideSource verified

Evidence: Laboratory research
Route: Marketed as an oral capsule and, in some listings, as an injectable preparation. No approved route exists.
Schedule: Not established. Vendor listings describe courses of daily use, but these come from sellers rather than from a regulator or a controlled trial.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of a knee joint showing cartilage, tendons and ligaments with illuminated repair pathways.

Single peptideSource verified

Evidence: Laboratory research
Route: Marketed as an oral capsule and, in some listings, as an injectable preparation. No approved route exists.
Schedule: Not established. Vendor listings describe courses of daily use, but these come from sellers rather than from a regulator or a controlled trial.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of the human brain with glowing synaptic activity and neural pathways.

Single peptideSource verified

Evidence: Human observational or case reports
Route: Intravenous infusion or intramuscular injection, administered in clinical settings in countries where it is registered.
Schedule: Registered use involves daily courses over a defined number of days rather than continuous use.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of the stomach, pancreas, liver and abdominal tissue with illuminated metabolic pathways.

CJC-1295 with DAC

CJC-1295 with DAC (drug affinity complex), also known as CJC-1295-DAC and in development as ConjuChem CJC-1295

Single peptideSource verified

Evidence: Human observational or case reports
Route: Subcutaneous injection in the published human trials
Schedule: Published trial work used single or infrequent subcutaneous administration, consistent with a multi-day half-life. No approved regimen exists.
Vials: 2 mg, 5 mg

View protocol6 citations

Cinematic 3D visualization of the stomach, pancreas, liver and abdominal tissue with illuminated metabolic pathways.

CJC-1295 without DAC

CJC-1295 without DAC, commonly called modified GRF(1-29) or tetrasubstituted GHRH(1-29)

Single peptideSource verified

Evidence: Laboratory research
Route: Subcutaneous injection is the route described in non-clinical use. No approved or trial-established route exists for this molecule.
Schedule: Not established. No approved label or dedicated human trial defines a frequency.
Vials: 2 mg, 5 mg

View protocol6 citations

Cinematic 3D visualization of the stomach, pancreas, liver and abdominal tissue with illuminated metabolic pathways.

CJC-1295 without DAC + Ipamorelin

BlendSource verified

Evidence: Laboratory research
Route: Vendor listings describe subcutaneous injection of a reconstituted blend. No approved route exists for the combination.
Schedule: Not established for the combination. Any schedule shown by a seller is a marketing convention, not a studied regimen.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of the human brain with glowing synaptic activity and neural pathways.

Single peptideSource verified

Evidence: Laboratory research
Route: Marketed as an oral capsule and, in some listings, as an injectable preparation. No approved route exists.
Schedule: Not established. Vendor listings describe courses of daily use, but these come from sellers rather than from a regulator or a controlled trial.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of the human brain with glowing synaptic activity and neural pathways.

Single peptideSource verified

Evidence: Animal research
Route: Studied by intravenous and other parenteral routes in older research. Sold as an injectable research chemical.
Schedule: Not established. Older studies used single or short-course administration.
Vials: No verified presentation recorded

View protocol1 citation

Single peptideSource verified

Evidence: Laboratory research
Route: Sold as a lyophilised research chemical for injection. No approved route.
Schedule: Not established. Vendor listings describe short repeated courses; this is seller convention, not evidence.
Vials: No verified presentation recorded

View protocol1 citation

Neutral molecular research illustration for Follistatin-344.

Follistatin-344

Single peptideSource verified

Evidence: Laboratory research
Route: Research reagent; no approved human route.
Schedule: Not established.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D macro visualization of a mitochondrion inside a cell with glowing energy transfer.

Single peptideSource verified

Evidence: Laboratory research
Route: Preclinical injection in animals. No approved human route.
Schedule: Not established in humans. Mouse work used intermittent administration.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D macro visualization of a mitochondrion inside a cell with glowing energy transfer.

GHK-Cu, copper tripeptide-1 (glycyl-L-histidyl-L-lysine copper complex)

Single peptideSource verified

Evidence: Controlled human trials
Route: Topical in the human evidence; subcutaneous and intraperitoneal in rodent models only
Schedule: Topical cosmetic studies applied a cream formulation on a daily schedule over a defined study period. No human schedule exists for injected GHK-Cu.
Vials: 50 mg, 100 mg

View protocol6 citations

Cinematic 3D macro cross-section of skin layers, collagen fibers and a hair follicle.

GHK-Cu + BPC-157 + TB-500 Blend (Glow)

BlendSource verified

Evidence: Laboratory research
Route: Vendor listings describe subcutaneous injection of a reconstituted blend. No approved route exists for the combination.
Schedule: Not established for the combination. Any schedule shown by a seller is a marketing convention, not a studied regimen.
Vials: 70 mg

View protocol3 citations

Cinematic 3D macro visualization of a mitochondrion inside a cell with glowing energy transfer.

Single peptideSource verified

Evidence: Animal research
Route: Oral supplementation is common. Intravenous and intramuscular preparations are marketed by clinics but are not FDA-approved.
Schedule: Supplement labels commonly describe daily oral use. No approved injectable schedule exists.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of the endocrine system with illuminated pituitary, thyroid, adrenal and pancreatic regions.

Single peptideSource verified

Evidence: Controlled human trials
Route: Intramuscular or subcutaneous injection of a reconstituted lyophilised powder, prescribed and supervised by a clinician.
Schedule: Approved products define injection schedules per indication, commonly several times weekly for male hypogonadism.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of the human heart and vascular network with illuminated circulation.

Single peptideSource verified

Evidence: Animal research
Route: Research studies used injection in animals. No approved human route.
Schedule: Not established in humans.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of skeletal muscle fiber bundles and tendons with illuminated recovery pathways.

Single peptideSource verified

Evidence: Laboratory research
Route: Sold as a lyophilised research reagent. No approved human route exists.
Schedule: Not established. No controlled human study defines a schedule.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of the stomach, pancreas, liver and abdominal tissue with illuminated metabolic pathways.

Ipamorelin (NNC 26-0161), Aib-His-D-2-Nal-D-Phe-Lys-NH2

Single peptideSource verified

Evidence: Human observational or case reports
Route: Human trials used intravenous administration. Subcutaneous use is the common non-clinical route and is not supported by an approval or a route-matched efficacy trial we could verify.
Schedule: Not established. No approved regimen exists. Published clinical work used short investigational intravenous dosing in a hospital setting.
Vials: 2 mg, 5 mg, 10 mg

View protocol6 citations

Cinematic 3D visualization of the endocrine system with illuminated pituitary, thyroid, adrenal and pancreatic regions.

Single peptideSource verified

Evidence: Human observational or case reports
Route: Investigational studies have used intravenous infusion or subcutaneous injection in controlled settings.
Schedule: Study-specific; infusion protocols and single injections have both been used in research.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of the stomach, intestines, liver and pancreas with warmly illuminated gut pathways.

KPV (Lys-Pro-Val), C-terminal tripeptide of alpha-MSH

Single peptideSource verified

Evidence: Animal research
Route: Oral and intraperitoneal in mouse models, including a nanoparticle-delivered oral formulation. No human route has been studied.
Schedule: Not established. No human schedule exists, and animal experiments used study-specific regimens.
Vials: 5 mg, 10 mg

View protocol6 citations

Cinematic 3D visualization of the stomach, pancreas, liver and abdominal tissue with illuminated metabolic pathways.

Single peptideSource verified

Evidence: Early human research
Route: Oral supplementation, or intravenous levocarnitine in approved deficiency indications. Compounded intramuscular injections sold for fat loss are not approved.
Schedule: Approved deficiency treatment schedules are defined in labelling and set by a clinician.
Vials: No verified presentation recorded

View protocol1 citation

Neutral molecular research illustration for Lipo-C lipotropic blend.

Lipo-C lipotropic blend

BlendSource verified

Evidence: Laboratory research
Route: Vendor listings describe subcutaneous injection of a reconstituted blend. No approved route exists for the combination.
Schedule: Not established for the combination. Any schedule shown by a seller is a marketing convention, not a studied regimen.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of immune cells signaling within tissue in teal and green light.

LL-37, human cathelicidin antimicrobial peptide (hCAP18 C-terminal fragment)

Single peptideSource verified

Evidence: Early human research
Route: Topical application in the human wound studies. Intravenous and other systemic routes are not established.
Schedule: Topical wound studies applied the peptide on study-defined schedules. No systemic human schedule is established.
Vials: 5 mg, 10 mg

View protocol6 citations

Cinematic 3D visualization of the endocrine system with illuminated pituitary, thyroid, adrenal and pancreatic regions.

Single peptideSource verified

Evidence: Controlled human trials
Route: Subcutaneous bioresorbable implant inserted by a healthcare professional in approved use.
Schedule: Implants are placed at approximately two-month intervals during periods of light exposure, per the approved label.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of the endocrine system with illuminated pituitary, thyroid, adrenal and pancreatic regions.

Single peptideSource verified

Evidence: Laboratory research
Route: Sold as a lyophilised research chemical for subcutaneous injection. No approved route.
Schedule: Not established. No controlled human study defines a schedule.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of the stomach, pancreas, liver and abdominal tissue with illuminated metabolic pathways.

Single peptideSource verified

Evidence: Animal research
Route: Animal studies used injection. No approved human route.
Schedule: Not established in humans.
Vials: No verified presentation recorded

View protocol1 citation

Neutral molecular research illustration for NAD+.

Single peptideSource verified

Evidence: Animal research
Route: Intravenous infusion in clinic settings, or oral precursor supplements. No approved injectable NAD+ product exists.
Schedule: Clinic infusion schedules are set by the provider and have no approved basis. Precursor trials used daily oral administration.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of the human brain with glowing synaptic activity and neural pathways.

Oxytocin Acetate

Single peptideSource verified

Evidence: Controlled human trials
Route: Approved use is intravenous infusion in a hospital. Intranasal oxytocin is used in research studies only.
Schedule: Titrated by infusion in obstetric care. Research studies of intranasal oxytocin typically used single administrations before a task.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of the human brain with glowing synaptic activity and neural pathways.

Single peptideSource verified

Evidence: Laboratory research
Route: Preclinical animal studies used injection. No human route exists.
Schedule: Not established in humans.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of the human brain with glowing synaptic activity and neural pathways.

Single peptideSource verified

Evidence: Laboratory research
Route: Preclinical injection in animals. No human route.
Schedule: Not established in humans.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of the human brain with glowing synaptic activity and neural pathways.

Single peptideSource verified

Evidence: Laboratory research
Route: Marketed as an oral capsule and, in some listings, as an injectable preparation. No approved route exists.
Schedule: Not established. Vendor listings describe courses of daily use, but these come from sellers rather than from a regulator or a controlled trial.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of DNA strands and mitochondria in a luminous cellular network.

Single peptideSource verified

Evidence: Laboratory research
Route: Preclinical injection in animals. No approved human route.
Schedule: Not established in humans.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of the human brain with glowing synaptic activity and neural pathways.

Single peptideSource verified

Evidence: Controlled human trials
Route: Subcutaneous injection in the abdomen or thigh, per the approved label
Schedule: As needed, at least 45 minutes before anticipated sexual activity, with the label limiting use to one dose in 24 hours and no more than eight doses per month.
Vials: No verified presentation recorded

View protocol2 citations

Cinematic 3D visualization of the stomach, pancreas, liver and abdominal tissue with illuminated metabolic pathways.

Single peptideSource verified

Evidence: Controlled human trials
Route: Subcutaneous injection, in every published human trial
Schedule: Once weekly in the published phase 2 and phase 3 programmes
Vials: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg

View protocol6 citations

Cinematic 3D visualization of the human brain with glowing synaptic activity and neural pathways.

Single peptideSource verified

Evidence: Animal research
Route: Intranasal solution in registered use; also sold as injectable research material.
Schedule: Registered use describes short daily courses.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of the stomach, pancreas, liver and abdominal tissue with illuminated metabolic pathways.

Single peptideSource verified

Evidence: Controlled human trials
Route: Subcutaneous injection once weekly (Ozempic, Wegovy) and oral tablet once daily (Rybelsus)
Schedule: Once weekly subcutaneously in the approved injectable presentations; once daily orally in the approved tablet presentation
Vials: 2 mg, 5 mg, 10 mg, 15 mg

View protocol6 citations

Cinematic 3D visualization of the human brain with glowing synaptic activity and neural pathways.

Single peptideSource verified

Evidence: Animal research
Route: Intranasal solution in registered Russian use; also sold as injectable research material.
Schedule: Registered use describes short daily courses rather than continuous use.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of the stomach, pancreas, liver and abdominal tissue with illuminated metabolic pathways.

Sermorelin acetate, GHRH(1-29) amide

Single peptideSource verified

Evidence: Controlled human trials
Route: Subcutaneous injection, the route in the former approved labelling
Schedule: Former approved labelling described once-daily subcutaneous injection at bedtime in paediatric growth hormone deficiency.
Vials: 2 mg, 5 mg, 6 mg

View protocol6 citations

Neutral molecular research illustration for SLU-PP-332.

Single peptideSource verified

Evidence: Laboratory research
Route: Preclinical injection in mice. No human route established.
Schedule: Not established in humans.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D macro cross-section of skin layers, collagen fibers and a hair follicle.

Single peptideSource verified

Evidence: Animal research
Route: Topical, as part of a finished cosmetic formulation. No injectable route is established or documented.
Schedule: Determined by the finished product, typically once or twice daily application as directed on the label. There is no separate peptide regimen.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of skeletal muscle fiber bundles and tendons with illuminated recovery pathways.

Single peptideSource verified

Evidence: Early human research
Route: Subcutaneous injection in the clinical programme, with ophthalmic formulations studied separately.
Schedule: Clinical trials used daily subcutaneous administration over defined study periods.
Vials: No verified presentation recorded

View protocol1 citation

Neutral molecular research illustration for TB-500.

TB-500 (vendor name for synthetic thymosin beta-4 fragments)

Single peptideSource verified

Evidence: Animal research
Route: Topical and intravenous in the published human studies of full-length thymosin beta-4. No published human study of the TB-500 fragment by any route was located.
Schedule: Not established for TB-500. Published human schedules belong to full-length thymosin beta-4 in topical and intravenous trials and cannot be transferred to a different molecule and route.
Vials: 5 mg, 10 mg

View protocol6 citations

Cinematic 3D visualization of the stomach, pancreas, liver and abdominal tissue with illuminated metabolic pathways.

Tesamorelin (EGRIFTA, EGRIFTA WR), a stabilised 44-amino-acid GHRH analogue

Single peptideSource verified

Evidence: Controlled human trials
Route: Subcutaneous injection into the abdomen, per the approved label
Schedule: Once daily subcutaneous injection, continuously, per the approved label.
Vials: 1 mg, 5 mg, 10 mg

View protocol6 citations

Cinematic 3D visualization of immune cells signaling within tissue in teal and green light.

Thymalin, a low-molecular-weight polypeptide complex extracted from calf thymus

Single peptideSource verified

Evidence: Human observational or case reports
Route: Intramuscular injection of a reconstituted lyophilisate, per Russian product labelling
Schedule: Russian product labelling describes daily intramuscular administration for short courses of roughly three to ten days, with courses sometimes repeated periodically.
Vials: 10 mg

View protocol6 citations

Cinematic 3D visualization of immune cells signaling within tissue in teal and green light.

Thymosin Alpha-1

Thymosin alpha-1 (thymalfasin), a synthetic 28-amino-acid acetylated thymic peptide

Single peptideSource verified

Evidence: Controlled human trials
Route: Subcutaneous injection in essentially all approved use and trial protocols
Schedule: Chronic hepatitis regimens used twice-weekly subcutaneous administration over months. Sepsis trials used short courses of daily or twice-daily administration over five to seven days.
Vials: 1.6 mg, 5 mg, 10 mg

View protocol6 citations

Cinematic 3D visualization of the stomach, pancreas, liver and abdominal tissue with illuminated metabolic pathways.

Single peptideSource verified

Evidence: Controlled human trials
Route: Subcutaneous injection once weekly
Schedule: Once weekly subcutaneous administration in every approved presentation and published trial
Vials: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 60 mg

View protocol6 citations

Cinematic 3D visualization of the human brain with glowing synaptic activity and neural pathways.

Vasoactive intestinal peptide (VIP); aviptadil is the synthetic pharmaceutical form

Single peptideSource verified

Evidence: Controlled human trials
Route: Intravenous infusion in critical COVID-19 trials; inhaled and nebulised in pulmonary hypertension and sarcoidosis studies
Schedule: Intravenous trial protocols used continuous infusion over hours per day for a few days. Inhaled studies used single or short-course administration. These are acute hospital protocols, not ongoing schedules.
Vials: No verified presentation recorded

View protocol6 citations

Cinematic 3D macro visualization of a mitochondrion inside a cell with glowing energy transfer.

Single peptideSource verified

Evidence: Controlled human trials
Route: Oral supplementation, intramuscular injection, or nasal spray, depending on the product and the cause of deficiency.
Schedule: Defined by the treating clinician; loading and maintenance schedules for deficiency are set out in approved labelling.
Vials: No verified presentation recorded

View protocol1 citation

Browse by research area